Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Celentyx
company
About
Celentyx is a CRO offering bespoke assay services in human immunology, including immuno-oncology, autoimmunity & inflammation, fibrosis.
- 11 - 50
Highlights
Details
- Last Funding Type
- Seed
- Industries
- Association,Biotechnology
- Founded date
- Jan 1, 2007
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Celentyx Ltd is a CRO offering bespoke assay services in human immunology, including immuno-oncology, autoimmunity & inflammation, fibrosis and neuroinflammation.Drawing on the World-leading expertise of Celentyx personnel, along with our close association with the MRC Centre for Immune Regulation and the Centre for Translational Inflammation Research enables the human immune system in health and disease to be investigated at the highest levels of resolution.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
—
Celentyx has raised a total of
—
in funding over 2 rounds. Their latest funding was raised on
Dec 12, 2007 from a Seed round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 12, 2007 | Seed | — | 1 |
Mercia Fund Managers
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Celentyx is funded by 1 investors.
Mercia Fund Managers
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Mercia Fund Managers
|
Yes | Seed |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
